Allianz Asset Management GmbH Sells 200,779 Shares of The Chemours Company $CC

Allianz Asset Management GmbH reduced its stake in The Chemours Company (NYSE:CC) by 30.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 468,824 shares of the specialty chemicals company’s stock after selling 200,779 shares during the quarter. Allianz Asset Management GmbH’s holdings in Chemours were worth $5,368,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. RFG Advisory LLC grew its stake in shares of Chemours by 52.7% in the 2nd quarter. RFG Advisory LLC now owns 109,231 shares of the specialty chemicals company’s stock valued at $1,251,000 after purchasing an additional 37,678 shares during the period. Yousif Capital Management LLC grew its stake in shares of Chemours by 1.6% in the 2nd quarter. Yousif Capital Management LLC now owns 62,386 shares of the specialty chemicals company’s stock valued at $714,000 after purchasing an additional 968 shares during the period. CWM LLC grew its stake in shares of Chemours by 34.7% in the 2nd quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company’s stock valued at $49,000 after purchasing an additional 1,104 shares during the period. Vanguard Personalized Indexing Management LLC grew its stake in shares of Chemours by 30.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 33,380 shares of the specialty chemicals company’s stock valued at $382,000 after purchasing an additional 7,827 shares during the period. Finally, Inspire Investing LLC grew its stake in shares of Chemours by 35.2% in the 2nd quarter. Inspire Investing LLC now owns 34,017 shares of the specialty chemicals company’s stock valued at $389,000 after purchasing an additional 8,861 shares during the period. 76.26% of the stock is currently owned by institutional investors.

Chemours Stock Performance

CC stock opened at $13.51 on Thursday. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The company has a 50 day moving average price of $15.33 and a 200 day moving average price of $13.04. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $22.38. The stock has a market capitalization of $2.02 billion, a PE ratio of -4.82 and a beta of 1.65.

Chemours (NYSE:CC) last posted its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm had revenue of $1.62 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the company posted $0.38 EPS. Chemours’s revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts forecast that The Chemours Company will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were given a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 2.6%. The ex-dividend date was Friday, August 15th. Chemours’s payout ratio is -12.50%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a report on Wednesday, October 8th. UBS Group boosted their target price on Chemours from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Zacks Research downgraded Chemours from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Royal Bank Of Canada set a $19.00 target price on Chemours and gave the stock an “outperform” rating in a report on Tuesday, October 14th. Finally, Mizuho reduced their target price on Chemours from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, October 16th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Chemours presently has a consensus rating of “Hold” and an average price target of $18.50.

Insiders Place Their Bets

In related news, CEO Denise Dignam acquired 4,068 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares of the company’s stock, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.47% of the stock is owned by company insiders.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.